Transgene SA (TNG.PA)

EUR 0.71

(-1.8%)

Long Term Debt Summary of Transgene SA

  • Transgene SA's latest annual long term debt in 2023 was 17 Thousand EUR , down -98.65% from previous year.
  • Transgene SA's latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Transgene SA reported annual long term debt of 1.25 Million EUR in 2022, down -48.67% from previous year.
  • Transgene SA reported annual long term debt of 2.44 Million EUR in 2021, down -36.51% from previous year.
  • Transgene SA reported quarterly long term debt of 11.57 Million EUR for 2023 Q1, up 820.45% from previous quarter.
  • Transgene SA reported quarterly long term debt of 17 Thousand EUR for 2023 Q4, down -99.89% from previous quarter.

Annual Long Term Debt Chart of Transgene SA (2023 - 1997)

Historical Annual Long Term Debt of Transgene SA (2023 - 1997)

Year Long Term Debt Long Term Debt Growth
2023 17 Thousand EUR -98.65%
2022 1.25 Million EUR -48.67%
2021 2.44 Million EUR -36.51%
2020 3.85 Million EUR -73.63%
2019 14.62 Million EUR -47.14%
2018 27.66 Million EUR -13.25%
2017 31.89 Million EUR -8.99%
2016 35.04 Million EUR 29.72%
2015 27.01 Million EUR -0.75%
2014 27.21 Million EUR 2.76%
2013 26.48 Million EUR -1.44%
2012 26.87 Million EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%
2009 - EUR 0.0%
2008 - EUR 0.0%
2007 - EUR 0.0%
2006 - EUR 0.0%
2004 4.71 Million EUR -6.72%
2003 5.05 Million EUR -8.72%
2002 5.54 Million EUR -5.96%
2001 5.89 Million EUR 0.39%
2000 5.86 Million EUR 7.59%
1999 5.45 Million EUR 42.33%
1998 3.83 Million EUR -5.27%
1997 4.04 Million EUR 0.0%

Peer Long Term Debt Comparison of Transgene SA

Name Long Term Debt Long Term Debt Difference
ABIONYX Pharma SA 1.1 Million EUR 98.456%
ABIVAX Société Anonyme 44.69 Million EUR 99.962%
Adocia SA 4.54 Million EUR 99.626%
Aelis Farma SA 2.04 Million EUR 99.17%
Biophytis S.A. 3.11 Million EUR 99.454%
Advicenne S.A. 15.89 Million EUR 99.893%
genOway Société anonyme 5.51 Million EUR 99.692%
IntegraGen SA 642.28 Thousand EUR 97.353%
Medesis Pharma S.A. 1.2 Million EUR 98.583%
Neovacs S.A. 650 Thousand EUR 97.385%
NFL Biosciences SA 39.2 Thousand EUR 56.636%
Plant Advanced Technologies SA 4.35 Million EUR 99.61%
Quantum Genomics Société Anonyme 1.96 Million EUR 99.133%
Sensorion SA 1.24 Million EUR 98.63%
Theranexus Société Anonyme 2.46 Million EUR 99.309%
TME Pharma N.V. - EUR -Infinity%
Valbiotis SA 3.89 Million EUR 99.564%
TheraVet SA 1 Million EUR 98.301%
Valerio Therapeutics Société anonyme 6.9 Million EUR 99.754%
argenx SE 15.35 Million EUR 99.889%
BioSenic S.A. 15.57 Million EUR 99.891%
Celyad Oncology SA 902 Thousand EUR 98.115%
DBV Technologies S.A. 4.52 Million USD 99.624%
Galapagos NV 4.94 Million EUR 99.656%
Genfit S.A. 62.25 Million EUR 99.973%
GeNeuro SA 6.49 Million EUR 99.738%
Hyloris Pharmaceuticals SA 344 Thousand EUR 95.058%
Innate Pharma S.A. 30.6 Million EUR 99.944%
Inventiva S.A. 25.61 Million EUR 99.934%
MaaT Pharma SA 5.42 Million EUR 99.687%
MedinCell S.A. 52.8 Million EUR 99.968%
Nanobiotix S.A. 41.66 Million EUR 99.959%
Onward Medical N.V. 16.3 Million EUR 99.896%
Oryzon Genomics S.A. 3.45 Million EUR 99.507%
OSE Immunotherapeutics SA 35.5 Million EUR 99.952%
Oxurion NV 117 Thousand EUR 85.47%
Pharming Group N.V. 123.65 Million EUR 99.986%
Poxel S.A. 40.14 Million EUR 99.958%
GenSight Biologics S.A. 1.04 Million EUR 98.378%
Financière de Tubize SA - EUR -Infinity%
UCB SA 2.87 Billion EUR 99.999%
Valneva SE 132.76 Million EUR 99.987%
Vivoryon Therapeutics N.V. - EUR -Infinity%